3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
3
Phase 2
3
Phase 1
2
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Small Cell Lung Carcinoma
18
Lymphoma, Large B-Cell, Diffuse
16
Leukemia, Myeloid, Acute
16
Hodgkin Disease
16
Lymphoma
15
Precursor Cell Lymphoblastic Leukemia-Lymphoma
13
Lymphoma, Non-Hodgkin
12
Lung Neoplasms
12
Lymphoma, Mantle-Cell
10
Lymphoma, Follicular
10
Leukemia
10
Lymphoma, B-Cell
7
Carcinoma, Non-Small-Cell Lung
7
Burkitt Lymphoma
6
Recurrence
5
Lymphoma, Large-Cell, Immunoblastic
5
Leukemia, Lymphocytic, Chronic, B-Cell
5
Lymphoma, T-Cell
4
Lymphoma, Large-Cell, Anaplastic
4
Lymphoma, B-Cell, Marginal Zone
4
Congenital Abnormalities
4
Waldenstrom Macroglobulinemia
3
Plasmablastic Lymphoma
3
Ovarian Neoplasms
3
Lymphoma, Primary Effusion
3
Leukemia, Myelomonocytic, Acute
3
Leukemia, Monocytic, Acute
3
Leukemia, Megakaryoblastic, Acute
3
Leukemia, Erythroblastic, Acute
3
Immunoblastic Lymphadenopathy
3
Interventions
pembrolizumab
6
aldesleukin
6
Cyclophosphamide
6
fludarabine phosphate
5
fludarabine
5
Nivolumab
4
durvalumab
3
Sorafenib
3
Radiotherapy
3
Filgrastim
3
Everolimus
3
Axitinib
3
Temozolomide
2
Peripheral Blood Stem Cell Transplantation
2
Isotretinoin
2
Ipilimumab
2
Interleukin-2
2
Interferon-alpha
2
Fluorouracil
2
Dexamethasone
2
Cyclosporine
2
Bevacizumab
2
vorolanib
1
tremelimumab
1
tocilizumab
1
talazoparib
1
spartalizumab
1
sargramostim
1
poly ICLC
1
palbociclib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Kidney Neoplasms
×
Etoposide
×
Clear all
NCT05384821
2026-03-18
MetroWilms
Centre Oscar Lambret
Phase 1/2
Recruiting
28 enrolled